Avalo Therapeutics, Inc.

Ownership Transactions Reported by 23 Insiders

Symbol
AVTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
540 Gaither Road, Suite 400, Rockville, MD

There are no Buy or Sell transactions made by insiders since 11/8/2023

Avalo Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Armistice Capital, Llc 10%+ Owner $398K Jun 26, 2023
Garry Arthur Neil CEO and Chairman of the Board, Director $101K Aug 13, 2024
Christopher Ryan Sullivan Chief Financial Officer $37.7K Aug 13, 2024
James Archie Harrell Jr Chief Commercial Officer $19.1K Dec 10, 2021
H. Jeffrey Wilkins Chief Medical Officer $17.3K Dec 10, 2021
Aaron Kantoff Director $4.93K Aug 13, 2024
Jonathan Goldman Director $4.93K Aug 13, 2024
Samantha Truex Director $4.93K Aug 13, 2024
June Almenoff Director $4.93K Aug 13, 2024
Mitchell Chan Director $4.93K Aug 13, 2024
Gilla Kaplan Director $4.93K Aug 13, 2024
Schond Greenway Cfo $2.02K Dec 10, 2021
Joseph M. Miller Director Mar 31, 2022
Magnus Persson Director Dec 20, 2023
Phil Gutry Director Dec 1, 2021
Illya Keith Maher Director Oct 15, 2021
Paul Varki Chief Legal Officer Jun 24, 2024
Stephen Smolinski Chief Commercial Officer Jan 4, 2022
Caissa Capital Management ltd. 10%+ Owner Jun 26, 2023
Michael F. Cola Chief Executive Officer, Director Oct 1, 2021
Suzanne Louise Bruhn Director Nov 10, 2021
Mittie Doyle Chief Medical Officer Jul 15, 2024
Sol J. Barer Director Jun 15, 2021

Recent Insider Transactions by Companies or Individuals for Avalo Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.